Caricamento...
Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies
Glasdegib is approved for treating acute myeloid leukemia in elderly patients at 100 mg once daily in combination with low‐dose cytarabine. Exposure‐efficacy analysis showed that the survival benefit of glasdegib was not glasdegib exposure‐dependent. The relationship between glasdegib exposure and a...
Salvato in:
| Pubblicato in: | J Clin Pharmacol |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891441/ https://ncbi.nlm.nih.gov/pubmed/32974950 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1742 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|